Want to see MIST full AI Analyst Report?
MIST Stock Chart & Stats
$2.10
-$0.02(-0.90%)
At close: 4:00 PM EST
$2.10
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$1.00 - $3.06
Previous CloseN/A
Volume143.50K
Average Volume (3M)1.31M
Market Cap
$151.89M
Enterprise Value$178.53M
Total Cash (Recent Filing)$184.22M
Total Debt (Recent Filing)$137.33M
Price to Earnings (P/E)―
Beta2.75
Next Earnings
Aug 12, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding124,497,980
10 Day Avg. Volume1,316,648
30 Day Avg. Volume1,314,317
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)4.06
Price to Sales (P/S)109.60
P/FCF Ratio-3.43
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue100.07
Enterprise Value/Gross Profit105.70
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$7.67Price Target Upside265.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$7.09M
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayA cash balance near $184M and management's runway guidance into H2 2027 materially reduce near-term refinancing risk and fund staged commercialization plus a Phase III trial, providing time to demonstrate commercial traction or secure repeatable revenue before capital markets are needed.
Rapid Commercial Launch ExecutionFast deployment of a national sales force and launch within months of approval shows operational capability to commercialize specialty cardiovascular drugs. This organizational execution supports sustained market access efforts and scales promotional reach as payer coverage and patient activation expand.
Major Payer/formulary ValidationSecuring a national PBM placement early materially improves patient access and reimbursement predictability. Coverage by Express Scripts validates formulary positioning and materially reduces structural barriers to uptake, enabling more efficient sales effort and long-term prescription growth as additional payers are added.
Bears Say
High LeverageDebt-to-equity near 3.8x for a loss-making biotech elevates refinancing and covenant risk and increases future dilution if equity financings are required. Over multiple quarters this leverage can constrain strategic flexibility, raise interest burden and complicate funding for organic growth or trials.
Sustained Negative Cash GenerationPersistent negative operating and free cash flow (~-$51M TTM) underscores dependence on external capital to fund operations and launches. Continued quarterly cash burn will erode runway absent accelerating product revenue or new financing, pressuring management to prioritize capital-efficient growth or raise dilutive funding.
Very Limited Product Revenue / Nascent Refill DynamicsExtremely low initial product revenue and early single-script behavior mean refill and repeat-use economics are unproven. Sustainable revenues require broader payer coverage, patient activation and repeat prescriptions; until these structural adoption dynamics are established, margin leverage from launch investments will remain weak.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $1.00 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $151.89M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of $0.19 by -$0.39.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 124,497,980 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.2 in its last earnings report, missing expectations of $0.19. Following the earnings report the stock price went down -9.474%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (265.08% Upside)
$7.67 (265.08% Upside)
Blogger Sentiment
Bullish
MIST Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 133.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.77%
12-Months-Change
Fundamentals
Return on Equity
-339.38%
Trailing 12-Months
Asset Growth
213.05%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
MIST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive early-launch narrative: Milestone executed a rapid launch, secured an important Express Scripts formulary placement, achieved early prescriber breadth (≈400 writers) and initiated a Phase III AFib-RVR program, while ending the quarter with a strengthened cash position (~$184M) and a planned, ROI-driven commercial strategy. Offsetting these positives are very small product revenues ($0.2M), elevated launch-driven commercial spend (+51.9% YoY), an increased quarterly net loss (~+25.5% YoY) and continued operating cash burn (~$23.7M in Q1). Coverage remains limited (~25% commercial) and scale/refill dynamics are in the earliest stages, so near-term sales will likely remain modest until broader payer coverage, patient activation and increased promotional frequency deliver deeper adoption.View all MIST earnings summariesMIST Stock 12 Month Forecast
Average Price Target
$7.67
▲(265.08% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
0.90% Insiders
0.06% Mutual Funds
0.15% Other Institutional Investors
96.18% Public Companies and
Individual Investors